Medicare AdvantagePrior AuthMedium impact
Brekiya® (dihydroergotamine mesylate) (New)
Humana·Neurology, Family Medicine, Internal Medicine +1 more·Medicare Advantage
Effective date
Dec 17, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Brekiya (dihydroergotamine mesylate) auto-injector for acute migraine and cluster headache treatment, with specific step therapy requirements including trial of other medications first.
Action Required
By December 17, 2025: Billing team must implement prior authorization requirements for Brekiya subcutaneous auto-injector prescriptions for Medicare Advantage patients. Providers must document previous treatment, intolerance, or contraindication to Ubrelvy plus one other specified medication for migraines, or two specified medications for cluster headaches. Update EMR templates to capture required step therapy documentation. Claims will be denied without proper prior authorization.